There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vicarious Surgical (RBOT – Research Report) and Evogene (EVGN – Research Report) with bullish sentiments.
Vicarious Surgical (RBOT)
In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Vicarious Surgical, with a price target of $1.50. The company’s shares closed last Monday at $0.38, close to its 52-week low of $0.32.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of
Currently, the analyst consensus on Vicarious Surgical is a Hold with an average price target of $1.13.
See today’s best-performing stocks on TipRanks >>
Evogene (EVGN)
Lake Street analyst Ben Klieve assigned a Buy rating to Evogene today and set a price target of $3.00. The company’s shares closed last Monday at $0.61, close to its 52-week low of $0.45.
According to TipRanks.com, Klieve is ranked #1725 out of 8631 analysts.
Currently, the analyst consensus on Evogene is a Moderate Buy with an average price target of $2.43.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RBOT:
